David Bleakman

Dr. Bleakman is a Research Advisor in Neuroscience and a recognized neuroscientist and expert in drug discovery and development. David is currently Chief Scientific Officer of Redpin Therapeutics, a chemogenetics biotechnology company. Previously, he served in multiple leadership roles over 25 years at Eli Lilly, including most recently as Vice President and Chief Scientific Officer in neuroscience research. He is an Adjunct Professor in Neuroscience at Mount Sinai School of Medicine, NY and has co-authored over 100 peer reviewed publications, several book chapters and numerous patents.

David received his Ph.D. from King’s College London, University of London and completed a postdoctoral fellowship at the University of Chicago.